Evaluation of M118 in Percutaneous Coronary Intervention (EMINENCE)

• Status: Completed
• Trial end date: 2009-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The primary objective is to evaluate the safety and feasibility of using M118 as an anticoagulant in the target population of subjects with stable coronary artery disease (CAD) undergoing percutaneous coronary intervention (PCI).

The secondary objectives are to evaluate the effect of M118 on procedural indices including procedure success, abrupt closure, post-procedure TIMI flow, and catheter thrombus.

Substudy Primary Objective The primary objective of the substudy is to characterize the pharmacokinetic and pharmacodynamic profile of M118 among subjects with stable coronary artery disease undergoing elective PCI.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Momenta Pharmaceuticals, Inc.
• Treatments: Calcium heparin; Heparin

Criteria

Inclusion Criteria:

• Age > 19 years

• Ability to give informed consent

• Documented stable CAD with a significant lesion in a native coronary artery amenable to PCI with one stent

• Planned single vessel intervention

Exclusion Criteria:

• Myocardial infarction or unstable angina within the prior 7 days

• Target lesion is a chronic total occlusion (present for longer than 3 months)

• Target lesion with angiographically visible thrombus or in-stent thrombosis

• Target lesion is in a bypass graft

• Planned use of a GP IIb/IIIa inhibitor or planned use of atherectomy including directional, rotational, or laser

• Known allergies or sensitivities to heparin, pork, or pork-containing products

• History of HIT

• Hemodynamic instability

• Stroke or Transient Ischemic Attack (TIA) in the prior 3 months

• Active bleeding or bleeding diathesis

• Trauma or major surgery in the preceding month or planned surgery or PCI within the 30 days after the index PCI

• Suspected aortic dissection

• Receiving oral anticoagulation therapy

• Receipt of LMWH or of UFH (except for that used during the diagnostic portion of the index procedure) within the prior 7 days

• ACT > 200 prior to study drug administration

• Severe, untreated hypertension at the time of the index PCI procedure (systolic blood pressure of > 180 mm Hg, diastolic blood pressure > 90 mm Hg)

• Hemoglobin level of less than 10.0 g/dl or a hematocrit below 30%

• Platelet count of less than 100,000 per cubic millimeter or more than 600,000 per cubic millimeter

• Creatinine clearance < 30 mL/min

• Any malignancy within the prior 5 years with the exception of non-melanoma skin cancers

• Prior enrollment in EMINENCE trial or currently receiving other experimental therapy

• Pregnant or lactating if subject is female

Substudy:

Inclusion:

• Ability to give informed consent

• Participation in the main study protocol

Exclusion:

-Inability to provide the blood specimens required by the substudy protocol